Georgia's Online Cancer Information Center

Find A Clinical Trial

Radiosurgery before Surgery for the Treatment of Brain Metastases

Status
Active
Cancer Type
Hematopoietic Malignancies
Trial Phase
Eligibility
18 Years and older, Male and Female
Study Type
Treatment
NCT ID
NCT04895592
Protocol IDs
RAD5234-21 (primary)
NCI-2021-02761
STUDY00001896
Study Sponsor
Emory University Hospital/Winship Cancer Institute

Summary

This early phase I trial identifies the side effects of stereotactic radiosurgery before surgery in treating patients with cancer that has spread to the brain (brain metastases). Radiation may stimulate an anti-tumor immune response. Giving stereotactic radiosurgery before surgery may reduce the risk of the cancer coming back after surgery.

Objectives

PRIMARY OBJECTIVE:
I. To determine the safety of pre-operative stereotactic radiosurgery (SRS) followed by surgery for brain metastasis.

SECONDARY OBJECTIVES:
I. To evaluate the immune niche in brain metastasis following SRS in the presence of low or high dose dexamethasone.
II. To evaluate the impact of pre-operative SRS on survival outcomes.

OUTLINE: Patients are assigned to 1 of 2 arms.

ARM A: Patients undergo SRS to the brain metastasis for 1-3 fractions over 1-14 days. Patients also receive low dose dexamethasone orally (PO) or intravenously (IV) for 2-21 days until the day of surgical resection. Patients then undergo surgical resection.

ARM B: Patients undergo SRS to the brain metastasis for 1-3 fractions over 1-14 days. Patients also receive high dose dexamethasone PO or IV for 2-21 days until the day of surgical resection. Patients then undergo surgical resection.

After completion of study intervention, patients are followed up for 120 days, and then every 12 weeks thereafter.

Eligibility

  1. Age >= 18 years
  2. Prior pathologically confirmed or suspected extracranial diagnosis of malignancy
  3. Brain metastases visible on contrasted magnetic resonance imaging (MRI) brain
  4. Eastern Cooperative Oncology Group (ECOG) performance status =< 2 (Karnofsky >= 60%)
  5. Life expectancy > 12 weeks as determined by the investigator
  6. Patients must have adequate organ function as determined by Neurosurgery to undergo surgery
  7. Willingness and ability of the subject to comply with scheduled visits, study procedures, and study restrictions
  8. Evidence of a personally signed informed consent indicating that the subject is aware of the neoplastic nature of the disease and has been informed of the procedures to be followed, the experimental nature of the therapy, alternatives, potential risks and discomforts, potential benefits, and other pertinent aspects of study participation
  9. Patient must have a negative pregnancy test, be actively taking oral contraceptives or have undergone a hysterectomy
**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.
Georgia CORE

 

Advancing Cancer Care through Partnerships and Innovation

Georgia CORE is a statewide nonprofit that leverages partnerships and innovation to attract more clinical trials, increase research, and promote education and early detection to improve cancer care for Georgians in rural, urban, and suburban communities across the state.